Product News: The Liposome Company
Executive Summary
The Liposome Company: Sales of Abelcet in the U.S. and overseas have exceeded $6 mil. so far in 1996, Princeton, N.J.-based firm says. "The launch of Abelcet has been extremely well received by physicians in the U.S." with "about 80% of the 50 hospitals that are the largest users of amphotericin B" buying the liposomal amphotericin formulation since its mid-December launch, TLC maintains. The company released the figures because it "is concerned about inaccurate information in the investment community concerning Abelcet and its sales prospects"...